Avid Bioservices マネジメント

マネジメント基準チェック /34

Avid Bioservicesの CEO はNick Greenで、 Jul2020年に任命され、の在任期間は 4.33年です。の年間総報酬は$ 4.48Mで、 14.5%給与と85.5%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.35%を直接所有しており、その価値は€ 2.67M 。経営陣と取締役会の平均在任期間はそれぞれ5.1年と5.3年です。

主要情報

Nick Green

最高経営責任者

US$4.5m

報酬総額

CEO給与比率	14.5%
CEO在任期間	4.3yrs
CEOの所有権	0.4%
経営陣の平均在職期間	5.1yrs
取締役会の平均在任期間	5.3yrs

経営陣の近況

Recent updates

CEO報酬分析

Avid Bioservices の収益と比較して、Nick Green の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jul 31 2024	n/a	n/a	-US$144m
Apr 30 2024	US$4m	US$650k	-US$141m
Jan 31 2024	n/a	n/a	-US$18m
Oct 31 2023	n/a	n/a	-US$12m
Jul 31 2023	n/a	n/a	-US$3m
Apr 30 2023	US$6m	US$642k	US$259k
Jan 31 2023	n/a	n/a	US$116m
Oct 31 2022	n/a	n/a	US$119m
Jul 31 2022	n/a	n/a	US$123m
Apr 30 2022	US$6m	US$600k	US$128m
Jan 31 2022	n/a	n/a	US$10m
Oct 31 2021	n/a	n/a	US$9m
Jul 31 2021	n/a	n/a	US$6m
Apr 30 2021	US$3m	US$421k	US$3m

報酬と市場: Nickの総報酬 ($USD 4.48M ) は、 German市場 ($USD 1.46M ) の同規模の企業の平均を上回っています。

報酬と収益: Nickの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Nick Green (59 yo)

4.3yrs

在職期間

US$4,475,343

報酬

Mr. Nicholas Stewart Green, also known as Nick, B.Sc., MBA, has been the President, Chief Executive Officer and Director at Avid Bioservices, Inc. since July 30, 2020. He served as the Chief Executive Offi...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Nicholas Green	President	4.3yrs	US$4.48m	0.35% € 2.7m
Daniel Hart	Chief Financial Officer	6.3yrs	US$1.44m	0.13% € 990.3k
Richard Richieri	Chief Operations Officer	5.1yrs	US$883.93k	0.070% € 528.5k
Mark Ziebell	VP, General Counsel & Corporate Secretary	12.4yrs	US$1.03m	0.10% € 785.8k
Matthew Kwietniak	Chief Commercial Officer	3.1yrs	US$975.87k	0.040% € 298.9k

5.1yrs

平均在職期間

59yo

平均年齢

経験豊富な経営陣: TEHPの経営陣は経験豊富で経験豊富です（平均在職期間は5.1年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Nicholas Green	President	4.3yrs	US$4.48m	0.35% € 2.7m
Joseph Carleone	Independent Chairman	7yrs	US$275.19k	0.16% € 1.2m
Catherine Mackey	Independent Director	5.3yrs	US$245.19k	0.026% € 195.5k
Gregory Sargen	Independent Director	7yrs	US$245.19k	0.015% € 113.1k
Jeanne Thoma	Independent Director	3.9yrs	US$245.19k	0.029% € 221.8k
Richard Hancock	Director	7yrs	US$240.19k	0.18% € 1.4m
Esther Alegria	Independent Director	3.4yrs	US$240.19k	0.017% € 129.3k

5.3yrs

平均在職期間

65yo

平均年齢

経験豊富なボード: TEHPの取締役会は経験豊富であると考えられます ( 5.3年の平均在任期間)。

Avid Bioservices マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Avid Bioservices, Inc., Annual General Meeting, Oct 16, 2024

Insufficient new directors

Insufficient new directors

Director recently bought €123k worth of stock

Independent Chairman recently bought €179k worth of stock

Avid Bioservices, Inc., Annual General Meeting, Oct 23, 2023

Recent updates

Punch and Associates Sends Letter to Board of Directors of Avid Bioservices, Inc

Funds managed by GHO Capital Partners LLP and Ampersand Management LLC entered into a definitive merger agreement to acquire Avid Bioservices, Inc. (NasdaqCM:CDMO) for approximately $850 million.

Funds managed by GHO Capital Partners LLP and Ampersand Management LLC entered into a definitive merger agreement to acquire Avid Bioservices, Inc. (NasdaqCM:CDMO) for approximately $850 million.

Avid Bioservices, Inc. Reiterates Earnings Guidance for the Fiscal Year 2025

First quarter 2025 earnings released: US$0.087 loss per share (vs US$0.034 loss in 1Q 2024)

Avid Bioservices, Inc. to Report Q1, 2025 Results on Sep 09, 2024

Avid Bioservices, Inc., Annual General Meeting, Oct 16, 2024

New major risk - Share price stability

Full year 2024 earnings released: US$2.23 loss per share (vs US$0.004 profit in FY 2023)

Avid Bioservices Provides Earnings Guidance for Fiscal Year 2025

Avid Bioservices, Inc. to Report Fiscal Year 2024 Final Results on Jul 02, 2024

Insufficient new directors

Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q

Avid Bioservices, Inc. announced delayed 10-Q filing

Now 30% overvalued after recent price rise

Avid Bioservices, Inc. announced that it expects to receive $160 million in funding

Avid Bioservices, Inc. announced that it expects to receive $160 million in funding

Now 30% overvalued after recent price rise

Insufficient new directors

Director recently bought €123k worth of stock

Avid Bioservices, Inc. Revises Revenue Guidance for the Full Fiscal Year 2024

New major risk - Share price stability

Avid Bioservices, Inc. to Report Q2, 2024 Results on Dec 07, 2023

Now 20% undervalued after recent price drop

Independent Chairman recently bought €179k worth of stock

Avid Bioservices, Inc. Reiterates Revenue Guidance for Full Fiscal Year 2024

First quarter 2024 earnings released: US$0.033 loss per share (vs US$0.025 profit in 1Q 2023)

Avid Bioservices, Inc. to Report Q1, 2024 Results on Sep 07, 2023

Avid Bioservices, Inc., Annual General Meeting, Oct 23, 2023

New minor risk - Profit margin trend

Full year 2023 earnings released: EPS: US$0.009 (vs US$2.08 in FY 2022)

Avid Bioservices, Inc. to Report Q4, 2023 Results on Jun 21, 2023

Investor sentiment deteriorates as stock falls 16%

Independent Director recently sold €130k worth of stock

Third quarter 2023 earnings released: EPS: US$0.007 (vs US$0.036 in 3Q 2022)

Investor sentiment deteriorates as stock falls 18%

Independent Director recently sold €80k worth of stock

Investor sentiment deteriorated over the past week

Second quarter 2023 earnings released: US$0.019 loss per share (vs US$0.057 profit in 2Q 2022)

Avid Bioservices, Inc. Revises Revenue Guidance for the Full Fiscal Year 2023

Avid Bioservices, Inc. to Report Q2, 2023 Results on Dec 06, 2022

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

First quarter 2023 earnings released: EPS: US$0.025 (vs US$0.10 in 1Q 2022)

Avid Bioservices, Inc. Provides Revenue Guidance for the Fiscal 2023

Avid Bioservices, Inc. to Report Q1, 2023 Results on Sep 06, 2022

Avid Bioservices, Inc., Annual General Meeting, Oct 18, 2022

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2022 earnings released: EPS: US$2.08 (vs US$0.057 in FY 2021)

Avid Bioservices, Inc. Provides Revenue Guidance for Fiscal 2023

Avid Bioservices, Inc.(NasdaqCM:CDMO) dropped from Russell 2000 Value Index

Avid Bioservices, Inc. to Report Q4, 2022 Results on Jun 29, 2022

Avid Bioservices Announces Launch of Analytical and Process Development Suites Within New, World-Class Viral Vector Development and Manufacturing Facility

Avid Bioservices, Inc. Reiterates Revenue Guidance for the Fiscal Year 2022

Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Avid Bioservices, Inc. to Report Q3, 2022 Results on Mar 08, 2022

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

First quarter 2022 earnings released: EPS US$0.10 (vs US$0.058 in 1Q 2021)

Independent Director Mark Bamforth has left the company

Full year 2021 earnings released: EPS US$0.057 (vs US$0.27 loss in FY 2020)

Avid Bioservices, Inc. Provides Revenue Guidance for 2022

Third quarter 2021 earnings released: EPS US$0.013 (vs US$0.063 loss in 3Q 2020)

Revenue beats expectations

Avid Bioservices, Inc. to Report Q3, 2021 Results on Mar 08, 2021

New 90-day high: €17.10

Avid Bioservices, Inc. Begins Phase 2 of its Myford Manufacturing Capacity Expansion Plan

Humanigen and Avid Bioservices Enter into cGMP Manufacturing Agreement for Covid-19 Therapeutic Candidate Lenzilumab in Support of Potential EUA Filing

マネジメント基準チェック /34